SVB Leerink analyst Jonathan Chang upgrades Calithera Biosciences (NASDAQ:CALA) from Market Perform to Outperform and raises the price target from $1 to $3.
SVB Leerink Upgrades Calithera Biosciences to Outperform, Raises Price Target to $3
SVB Leerink analyst Jonathan Chang upgrades Calithera Biosciences (NASDAQ:CALA) from Market Perform to Outperform and raises the price target from $1 to $3.
Related Posts
Investors Cheer Chegg’s Earnings, Analysts Raise Price Targets, Highlight International Prospects
Needham analyst Ryan MacDonald reiterated a Buy rating and $28 price target on Chegg Inc (NYSE: CHGG) after the company put up a solid topline beat bolstered by an impressive level of leverage in the model that he expects will flow through into 4Q22 & FY23.
Krispy Kreme Has Reported Its Q2 Earnings And Investors Are Not Happy: Here’s Why The Stock Is Moving Today
Shares of Krispy Kreme Inc. (NASDAQ: DNUT) are falling on Wednesday morning following a worse-than-expected earnings report.
Is Now the Time To Buy Anaplan And Workday?
Analysts at Barclays believe Anaplan, Inc (NYSE: PLAN) and Workday, Inc. (NASDAQ: WDAY) are positioned for a solid second half of 2021 following underperformance since the onset of the pandemic relative to the broader sof